OCT Clinical Trials Appoints Maxime Stevens as Chief Strategy and Development Officer; Poises for Global Expansion

Monday, September 23, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

OCT, Eastern Europe's leading CRO, looks to expand its presence into EMEA, Israel, South Africa, Europe and the United States with appointment of Maxime Stevens to the position of Chief Strategy and Development Officer.

SAINT PETERSBURG, Russia, Sept. 23, 2019 /PRNewswire-PRWeb/ -- OCT Clinical Trials, a leading CRO with operations

in Eastern Europe, today announced that it has appointed Maxime Stevens as Chief Strategy and Development Officer. In her role, she is responsible for establishing business development vision, creating roadmaps for global expansion, driving operational excellence and leading short- and long-term global strategy growth operations for the entire company.

"It is both an honor and pleasure for me to be joining OCT Clinical Trials as their Chief Strategy and Development Officer," Stevens said. "The people are extremely skilled, experienced and passionate about not only our work, but also each other, our sponsors and our partners."

Maxime brings more than 25 years' experience in executive leadership, developing Global BD and Operations groups for both American and European companies, including United States Surgical Corporation, Cyberonics Inc., Pierrel Research International AG and Optimapharm. As CEO for Pierrel Research International AG, Maxime was instrumental in wholly restructuring a troubled global company with 28 offices, increasing investments, backlog and revenue pipelines by more than 200%, and securing SIX Swiss Exchange listing of the merged companies in 2014.

Maxime possesses a strong track record of driving long-term growth, operational excellence and expansion of new geographic and channel opportunities for prominent players in the industry. Her extensive international experience, most notably in MENA, Africa, Europe and the United States, is a valuable asset for OCT Clinical Trials as the company moves toward global expansion.

Maxime is also known for her seven-year period running operations for South Africa's branch of the World Health Organization (WHO). Maxime was recognized by WHO for Outstanding Contribution to Ethics in Business and Humanity, and was an Honored Member of International WHO's WHO of Professionals in both 2013 and 2014. She also sat for four years on the FDA advisory and ethical boards for Innovative Medical Device approvals.

"I look forward to supporting both strategic onward growth and success of the company, and inspiring our people to learn even more, and become even more. Our best work happens when we embrace making a difference — and then we achieve it," Maxime added.

Having already gained a sizable market share of trials in Eastern Europe and CIS region, OCT is now taking the significant step of expanding its presence into EMEA, Israel, South Africa, Europe and the United States. With this strategic reinforcement, they will continue to provide the tailor-made solutions they are already known for, now to a broader pool of pharma, biotech and medical device companies.

"We're a full-service CRO with over 300 projects in our portfolio, solid technological infrastructure and well-run processes with all the main sites within the Eastern European and CIS region," said Dmitry Sharov, OCT Group President. "We realize that our services and approach are in high demand, not only for sponsors within the region, but for companies worldwide. Maxime Stevens has the proven experience and expertise to strategically develop and drive our expertise into the global arena, and amplify the image of a CRO with an impeccable reputation."

About OCT Clinical Trials OCT Clinical Trials is the leading CRO in Russia, with operations in Central and Eastern Europe and the CIS region. With a team of over 200 professionals, the company provides a full range of high-quality clinical research services for phase I-IV and BE studies. With strong local expertise and focus on quality, OCT ensures seamless clinical trial conduct and drug registration on time and within budget. OCT's experienced team delivers both standalone services such as medical writing, consultancy, project management/monitoring, data management/biostatistics and turnkey service for clinical development. Since 2005, OCT Clinical Trials has worked on over 300 full-service and functional service projects in more than 20 therapeutic areas. Learn more at http://www.OCT-ClinicalTrials.com.


SOURCE OCT Clinical Trials

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z



Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store